SciSparc Ltd. (SPRC)

1.2100 -0.0200 (-1.63%) At close: 04:00PM EDT

SciSparc Ltd.

Tower A
2nd Floor 20 Raul Wallenberg Street
Tel Aviv 6971916
Israel
972 7 334 47180
https://scisparc.com

Sector(s): Healthcare
Industry: Biotechnology
Full-time employees: 3

Key executives

Name	Title	Pay	Exercised	Year born
Mr. Oz Adler CPA	CEO & CFO	363k	N/A	1987
Mr. Itschak Shrem	President & Director	219k	N/A	1947
Dr. Adi Zuloff-Shani Ph.D.	Chief Technologies Officer	274k	N/A	1969

Amounts are as of 31 December 2023, and compensation values are for the last fiscal year ending on that date. Pay includes salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

SciSparc Ltd., a clinical-stage pharmaceutical company, develops drugs based on cannabinoid therapies. Its drug development programs include SCI-110 for the treatment of Tourette syndrome and Alzheimer's disease and agitation; SCI-160 for the treatment of pain; SCI-210 for the treatment of autism spectrum disorder and status epilepticus; and CannAmide, an anti-inflammatory and chronic pain solution. The company has an agreement with Procaps to develop and commercially manufacture SCI-110 and CannAmide, a palmitoylethanolamide oral tablet in softgel capsule form. It also has an agreement with The Israeli Medical Center for Alzheimer's to conduct a phase IIa clinical trial to evaluate the safety, tolerability, and efficacy of SCI-110 in patients with Alzheimer's disease and agitation; and a collaboration with Clearmind Medicine Inc. The company was formerly known as Therapix Biosciences Ltd. and changed its name to SciSparc Ltd. in January 2021. SciSparc Ltd. was incorporated in 2004 and is headquartered in Tel Aviv-Yafo, Israel.

Corporate governance

SciSparc Ltd.’s ISS governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while 10 indicates higher governance risk.